Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) will face an 11.5% price cut in August under Japan’s quarterly price review, which basically triggers re-pricing for better-than-expected sales, Jiho learned. This brings down prices for three other I/O agents as well, slapping…
To read the full story
Related Article
- Imfinzi Faces Price Slash of 25%, Polivy 15% in February: Quarterly Re-Pricing
November 16, 2023
- Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
- Keytruda to Get 17.5% Price Cut in February
November 13, 2019
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
August 29, 2019
- Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
- Maviret Faces 25% Price Slash in Quarterly Review
November 14, 2018
- Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…